GRAND ROUNDS 
Zoom
Fellow Expert Talks

Patient Viewing Cancelled

Mohs Micrographic Surgery for Melanoma

Partik Singh, MD, MBA, Micrographic Surgery and Dermatologic Oncology Fellow, UCSF

Objectives:

Understand melanoma patient selection for Mohs surgery or excisional surgery

Discuss pre/postoperative considerations for Mohs surgery for melanoma

Illustrate surgical technique for staging/treatment of melanoma with Mohs surgery

The Grey Zone: Tools to Navigate Surgical Uncertainty

Divya Seth, MD, MPH, Micrographic Surgery and Dermatologic Oncology Fellow, UCSF

Objectives:

Can we define clinical and surgical uncertainty?

Case 1: approaches for large and ill defined tumors

Case 2: implementing guidelines and more for high grade SCC

Superficial radiation therapy as a standalone treatment for skin cancers: What dermatologists need to know

Ayan Kusari, MD, Micrographic Surgery and Dermatologic Oncology Fellow, UCSF

Objectives:

Explain how SRT works and its effectiveness in treating various types of skin cancers compared to other treatment modalities.

Discuss the clinical guidelines and criteria for selecting patients who would benefit most from SRT as a standalone treatment.

Analyze potential adverse effects of SRT, including long-term outcomes and patient quality of life considerations.

A Review of Cutaneous Mucormycosis

Sarah Pourakbar, MD, Complex Medical Dermatology Fellow, UCSF

Objectives:

Review epidemiology, risk factors, and clinical features of cutaneous mucormycosis for early recognition and initiation of treatment.

Discuss practice gaps in the current guidelines for medical and surgical management of cutaneous mucormycosis and review future directions for improved outcomes.

Speaker Disclosures: Partik Singh, MD, MBA, Divya Seth, MD, MPH, Ayan Kusari, MD, Sarah Pourakbar, MD have all stated that they have no financial relationships to disclose.

Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.